Health & Fitness
Fri, January 27, 2012
NEW YORK--([ BUSINESS WIRE ])--Levi & Korsinsky is investigating the Board of Directors of Micromet, Inc. (aMicrometa or the aCompanya) (Nasdaq: MITI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Amgen Inc. (Nasdaq: AMGN). Under the terms of the transaction, Micromet shareholders will receive $11 per share of Micromet stock they own. The transaction has a total approximate value of $1.16 billion.
Click here to learn more about the investigation: [ http://www.zlk.com/micromet-miti ], or call: 877-363-5972.
The investigation concerns whether the Micromet Board of Directors breached their fiduciary duties to Micromet stockholders by failing to adequately shop the Company before entering into this transaction and whether Amgen is underpaying for Micromet shares, thus unlawfully harming Micromet stockholders. In particular, at least one analyst set a price target of $12.00 per Micromet share.
If you own common stock in Micromet and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at [ jlevi@zlk.com ] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit [ http://www.zlk.com ].
Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major litigations involving mergers and acquisitions. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
